These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
110 related articles for article (PubMed ID: 11374981)
1. Total synthesis of SR 121463 A, a highly potent and selective vasopressin v(2) receptor antagonist. Venkatesan H; Davis MC; Altas Y; Snyder JP; Liotta DC J Org Chem; 2001 Jun; 66(11):3653-61. PubMed ID: 11374981 [TBL] [Abstract][Full Text] [Related]
2. Stereoselective synthesis of C-substituted morpholine derivatives using reductive etherification reaction: total synthesis of chelonin C. Gharpure SJ; Prasad JV J Org Chem; 2011 Dec; 76(24):10325-31. PubMed ID: 22059866 [TBL] [Abstract][Full Text] [Related]
3. Nonpeptide antagonists for vasopressin receptors. Pharmacology of SR 121463A, a new potent and highly selective V2 receptor antagonist. Serradeil-Le Gal C Adv Exp Med Biol; 1998; 449():427-38. PubMed ID: 10026834 [TBL] [Abstract][Full Text] [Related]
4. Therapeutic potential of vasopressin receptor antagonists. Ali F; Guglin M; Vaitkevicius P; Ghali JK Drugs; 2007; 67(6):847-58. PubMed ID: 17428103 [TBL] [Abstract][Full Text] [Related]
5. Binding properties of a selective tritiated vasopressin V2 receptor antagonist, [H]-SR 121463. Serradeil-Le Gal C; Raufaste D; Double-Cazanave E; Guillon G; Garcia C; Pascal M; Maffrand JP Kidney Int; 2000 Oct; 58(4):1613-22. PubMed ID: 11012895 [TBL] [Abstract][Full Text] [Related]
6. Characterization of SR 121463A, a highly potent and selective, orally active vasopressin V2 receptor antagonist. Serradeil-Le Gal C; Lacour C; Valette G; Garcia G; Foulon L; Galindo G; Bankir L; Pouzet B; Guillon G; Barberis C; Chicot D; Jard S; Vilain P; Garcia C; Marty E; Raufaste D; Brossard G; Nisato D; Maffrand JP; Le Fur G J Clin Invest; 1996 Dec; 98(12):2729-38. PubMed ID: 8981918 [TBL] [Abstract][Full Text] [Related]
7. Total synthesis and stereochemical revision of acortatarins A and B. Sudhakar G; Kadam VD; Bayya S; Pranitha G; Jagadeesh B Org Lett; 2011 Oct; 13(20):5452-5. PubMed ID: 21955040 [TBL] [Abstract][Full Text] [Related]
12. An efficient one pot regioselective synthesis of a 3,3'-spiro-phosphonylpyrazole-oxindole framework via base mediated [1,3]-dipolar cycloaddition reaction of the Bestmann-Ohira reagent with methyleneindolinones. Shelke AM; Suryavanshi G Org Biomol Chem; 2015 Aug; 13(32):8669-75. PubMed ID: 26177837 [TBL] [Abstract][Full Text] [Related]
13. Diabetes-induced albuminuria: role of antidiuretic hormone as revealed by chronic V2 receptor antagonism in rats. Bardoux P; Bruneval P; Heudes D; Bouby N; Bankir L Nephrol Dial Transplant; 2003 Sep; 18(9):1755-63. PubMed ID: 12937221 [TBL] [Abstract][Full Text] [Related]
14. Azomethine ylide cycloaddition/reductive heterocyclization approach to oxindole alkaloids: asymmetric synthesis of (-)-horsfiline. Cravotto G; Giovenzana GB; Pilati T; Sisti M; Palmisano G J Org Chem; 2001 Dec; 66(25):8447-53. PubMed ID: 11735524 [TBL] [Abstract][Full Text] [Related]
15. Successful long-term treatment of hyponatremia in syndrome of inappropriate antidiuretic hormone secretion with satavaptan (SR121463B), an orally active nonpeptide vasopressin V2-receptor antagonist. Soupart A; Gross P; Legros JJ; Alföldi S; Annane D; Heshmati HM; Decaux G Clin J Am Soc Nephrol; 2006 Nov; 1(6):1154-60. PubMed ID: 17699341 [TBL] [Abstract][Full Text] [Related]
16. Preparation of highly potent and selective non-peptide antagonists of the arginine vasopressin V1A receptor by introduction of a 2-ethyl-1H-1-imidazolyl group. Shimada Y; Akane H; Taniguchi N; Matsuhisa A; Kawano N; Kikuchi K; Yatsu T; Tahara A; Tomura Y; Kusayama T; Wada K; Tsukada J; Tsunoda T; Tanaka A Chem Pharm Bull (Tokyo); 2005 Jul; 53(7):764-9. PubMed ID: 15997131 [TBL] [Abstract][Full Text] [Related]
17. Effects of novel vasopressin receptor antagonists on renal function and cardiac hypertrophy in rats with experimental congestive heart failure. Bishara B; Shiekh H; Karram T; Rubinstein I; Azzam ZS; Abu-Saleh N; Nitecki S; Winaver J; Hoffman A; Abassi ZA J Pharmacol Exp Ther; 2008 Aug; 326(2):414-22. PubMed ID: 18467593 [TBL] [Abstract][Full Text] [Related]
18. Vasopressin-2 receptor antagonist attenuates the ability of the lungs to clear edema in an experimental model. Guetta J; Klorin G; Tal R; Berger G; Ismael-Badarneh R; Bishara B; Sabo E; Abassi Z; Azzam ZS Am J Respir Cell Mol Biol; 2012 Nov; 47(5):583-8. PubMed ID: 22700868 [TBL] [Abstract][Full Text] [Related]
19. Vasopressin receptor antagonists for the treatment of hyponatremia: systematic review and meta-analysis. Rozen-Zvi B; Yahav D; Gheorghiade M; Korzets A; Leibovici L; Gafter U Am J Kidney Dis; 2010 Aug; 56(2):325-37. PubMed ID: 20538391 [TBL] [Abstract][Full Text] [Related]
20. Total synthesis of (-)-reveromycin a. El Sous M; Ganame D; Tregloan PA; Rizzacasa MA Org Lett; 2004 Aug; 6(17):3001-4. PubMed ID: 15330668 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]